ERBB2 and neoplasm: Histologic evaluation of tumor-infiltrating lymphocytes (TILs) is emerging as a promising biomarker in solid tumors and has reached level IB-evidence as a prognostic marker in triple-negative (TNBC) and HER2-positive breast cancer3–5.